083790.KQ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2024 @ 08:30):
Our systems believe the stock currently is undervalued by 0.44% compare to its pairs and should correct upwards.

Stats
Dagens volum	144 802
Gjennomsnittsvolum	199 924
Markedsverdi	205.94B
EPS	KRW-98.15 ( Q1 \| 2024-03-31 )
Neste inntjeningsdato	( KRW0 ) 2024-08-14
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	KRW8.42 (0.31%)

Korrelasjon (AI algo v.1.1b): Undervalued: 0.44% KRW2 711.77 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.11 (neutral)

Kort: 0.00 (neutral)

Signal:(53.394) Neutral

CrystalGenomics, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

CrystalGenomics, Inc. Korrelasjon - Valuta/Råvare

-0.38
( neutral )

-0.17
( neutral )

0.05
( neutral )

-0.13
( neutral )

0.08
( neutral )

0.36
( neutral )

CrystalGenomics, Inc. Økonomi

Annual	2023
Omsetning:	KRW4.88B
Bruttogevinst:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
Omsetning:	KRW4.88B
Bruttogevinst:	KRW1.46B (29.86 %)
EPS:	KRW-665.90

FY	2023
Omsetning:	KRW17.46B
Bruttogevinst:	KRW9.07B (51.96 %)
EPS:	KRW132.36

FY	2022
Omsetning:	KRW16.25B
Bruttogevinst:	KRW8.47B (52.13 %)
EPS:	KRW117.19

Financial Reports:

No articles found.

CrystalGenomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CrystalGenomics, Inc.

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.